Please login to the form below

Not currently logged in
Email:
Password:

People, January, 2007

Steve Mileshas been appointed as UK marketing director at Trinity Chiesi. Steve joins the company from Fresenius Kabi where he spent three years as sales and marketing director

Steve Miles has been appointed as UK marketing director at Trinity Chiesi. Steve joins the company from Fresenius Kabi where he spent three years as sales and marketing director. Prior to this, he was on the UK Boards of Schering-Plough and Novo Nordisk.

GlaxoSmithKline (GSK) has appointed Adrian Rawcliffe as senior vice president of its worldwide business development, research and development. Most recently, Adrian was managing partner and president of SR One, GSK's venture capital firm, a position he has held since 2005. In his new role, Adrian will report to Dr Moncef Slaoui, chairman of R&D, and will be responsible for all business development activities, including in-licensing, collaborations and alliance management.

Rosemont Pharmaceuticals has appointed Kevin James as chairman. Previously, Kevin was managing director of Wyeth UK and Ireland. Rosemont specialises in the development, manufacturing and marketing of oral liquid medicines.

Dr Kevin Bryett has been appointed as chief executive officer of Vaccine Research International. Dr Bryett has more than 20 years' commercial experience of global vaccines. He qualified as a physician from St George's Medical School and, after a time as a practising doctor, joined the pharma industry in 1982. He has held a number of senior posts, including vice president of European commercial operations for Aventis Pasteur MSD. More recently, he was the vice president of global commercial operations at Chiron Vaccinces and was part of the team that managed the $1bn takeover of PowderJect Pharmaceuticals.

Anders Ullman has been appointed as executive vice president of research and development at Nycomed, a role that became effective from the firm's completion of its acquisition of Altana Pharma. Anders has spent 16 years in medical research and development, most recently as senior vice president of research and development at European biopharma firm, Biovitrum.

Cambridge Antibody Technology (CAT) has announced three promotions: Gaynor Fryers, Ian Anderson and Andy Williams. Gaynor is promoted to vice president of business development. She joined CAT in 2004 and prior to her promotion was business development director. Before joining the company, she served as group commercial director at Bespak. Ian has been promoted to vice president of discovery - respiratory and inflammation. In his new role, Ian, who joined CAT in 1998, will be responsible for leading the respiratory and inflammation team within the company's drug discovery unit. Andy has been promoted to vice pre-sident discovery - programme management. He joined the firm in 1993 following a post-doctoral fellowship at the University of British Columbia in Vancouver, Canada.

~

Dr Bruce Chabner has been appointed as non-executive director at biopharmaceutical company, PharmaMar. Dr Chabner is a leading cancer expert and has received awards in recognition of his achievements, including the Bob Pinedo Award for Contributions to Improvement in the Care of Cancer Patients. He was director of the National Cancer Institute for 12 years and has published over 200 scientific papers.

Synovate Healthcare has appointed Kris Weinberg as vice president of longitudinal oncology services. In his new role, Kris will develop and commercialise the company's longitudinal oncology data product initiatives. He has 16 years' experience in oncology and has worked previously in sales, reimbursement and product development roles in the pharma sector. Prior to joining Synovate, Kris was part of the commercial team at Genomic Health.

Genus Pharmaceuticals has appointed Puja Thapar as a business development executive. Puja has four years' industry experience, split evenly between regulatory affairs and business development.

Monica Shulman has been appointed as associate director at Reynolds-MacKenzie, where she will be responsible for Amgen and Pfizer projects. She joins from Burson-Marsteller, where her key clients included Pfizer and Bristol-Myers Squibb. In a career that spans 12 years, Monica has also served at Ketchum and the Shire Health Group. She has worked in many areas, but has particular experience in mental health, oncology and vaccines.

Cohn & Wolfe London has promoted associate director Pat Hindley to the board, where she will be responsible for the agency's growing consumer health portfolio. Pat will continue to oversee clients including NiQuitin and will work alongside consumer division managing director, Claire Mann. Pat joined Cohn & Wolfe in 2004 and has managed PR programmes aimed at both consumers and healthcare professionals.

Healthcare PR agency Athena Medical PR has appointed Philippa Mallaband as associate director. Pip joins the firm from Chandler Chicco Agency where she was team leader and has a wealth of therapeutic and operational business experience. She began her career at Shire Hall Communications and went on to work for several other top PR agencies. In her new role, she will head up the oncology account for Pfizer and the neurology portfolio for Boehringer Ingelheim.

Clew Communications has promoted Stuart Mayell to associate director. Stuart, who joined the agency from the Red Consultancy, has been at Clew for two years and worked in PR for more than 10 years. In addition, Clew has appointed Rebecca Carnegie as account executive. Rebecca has two years' experience working in PR and is a biochemistry graduate from Manchester University.

ScopeMedical has made three new appointments: Carrie Coles and Aysha Windebank as senior account managers and Saul Kitchen who has joined the team permanently after a stint as a freelancer. Carrie has seven years' communications experience and a BSc in health studies from King's College London. Aysha has 10 years of international healthcare communications experience with an account management and operational marketing background. Saul has 15 years' experience in the creative industry and has worked for a number of leading advertising and design agencies, as well as medical education firms.

hsdcommunications has promoted Emma O'Callaghan and Kate Refson to senior account manager and account manager, respectively. Emma has been at the agency for four years working closely with associate director, Cerys Evans, to develop a presence in Ireland and creating medical and DTC programmes for Shire Pharmaceuticals and MÛInlycke Healthcare. Kate will continue to manage key accounts in hsdcommunications' consumer healthcare division.

Jango Communications has appointed Martine Garabette as senior account director. Martine joins Jango after more than five years at the medical communications division of McCann Healthcare.

Eurocom Healthcare Communications has hired Sang Tae Kim as account manager. Sang, who worked previously at Euro RSCG Healthcare, has a degree in biotechnology and has worked in a number of therapy areas including Parkinson's disease and arthritis.

Adventis Group has made a number of key changes to the board: Peter Linnell has been appointed as finance director, replacing Allan Collins who will become non-executive director. Peter has worked in marketing communications for more than 20 years and joins the company from Lowe & Partners where he was chief financial officer.

RSA has appointed Tony Forbes-Leith and Nicola Harding to head up its new central London office. They have more than 50 years' combined life sciences-related recruitment experience between them and, until recently, were both executive directors at Talentmark.

Chase has appointed Clare Jones as recruitment consultant, West Midlands and Trent. Clare has more than seven years' experience in recruitment.

 

Share

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
Complete Medical Communications (CMC)

CMC is a leading global agency dedicated to healthcare communications across the lifecycle. We combine scientific acumen, excellence in delivery...

Latest intelligence

patients
Retaining reader value in plain language summaries of clinical studies
Balancing the risk of misinterpretation with the public’s ability to understand simplified plain-language summaries...
Can we talk about the ego-bias and chemicals influencing your target audience’s behaviour?
Over the Summer, the Page & Page team became fascinated by two books on this very subject. Two books from one author, Dean Burnett, an eminent neuroscientist, lecturing at Cardiff...
Paris
Making Europe a leader in bioscience: boosting trust and opening minds
A vision of Paris as Europe's leading hub for life sciences innovation...

Infographics